# Pharmaron Beijing Co., Ltd.
# 康龍化成(北京)新藥技術股份有限公司

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 3759)**

## INSIDE INFORMATION ANNOUNCEMENT REGARDING THE ESTIMATE FOR INTERIM RESULTS OF 2026

This announcement is made by Pharmaron Beijing Co., Ltd. (the "**Company**" and together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The following is the estimate of the Company for the interim results of 2026. The financial data contained in this results estimate has not been audited and is, except for non-IFRSs (International Financial Reporting Standards) adjusted net profit attributable to owners of the parent or as otherwise indicated, prepared in accordance with the PRC Accounting Standards for Business Enterprises.

### I. ESTIMATE FOR INTERIM RESULTS OF 2026

1. Period for the results estimate: January 1, 2026 to June 30, 2026

2. Results estimate: The estimated net profit will be positive and represent a year-on-year increase.

| Item | Current reporting period | Same period last year |
|---|---|---|
| Revenue | Revenue: 7,471.5029 million – 7,664.7315 million<br><br>Growth compared with the same period of last year: 16%-19% | Revenue: 6,440.9508 million |
| Net profit attributable to owners of the parent | Profit: 729.4516 million – 771.5354 million<br><br>Growth compared with the same period of last year: 4%-10% | Profit: 701.3958 million |
| Net profit attributable to owners of the parent excluding non-recurring gains or losses *(Note 2)* | Profit: 674.8566 million – 706.6895 million<br><br>Growth compared with the same period of last year: 6%-11% | Profit: 636.6572 million |
| Basic earnings per share | Profit: 0.4024/share – 0.4256/share | Profit: 0.3984/share |
| Non-IFRSs adjusted net profit attributable to owners of the parent *(Note 3)* | Profit: 884.1705 million – 921.9556 million<br><br>Growth compared with the same period of last year: 17%-22% | Profit: 755.7013 million |

*Note 1:*

The "million" in this results estimate is in RMB million, unless otherwise defined.

*Note 2:*

According to the preliminary estimate by the Company, the non-recurring gains or losses attributable to owners of the parent for the interim period of 2026 would be in the range of approximately RMB53 million and RMB63 million, which mainly include government subsidies recognized in the current profit or losses and gains on changes in fair value of other non-current financial assets, etc.

*Note 3:*

To supplement the financial statements prepared by us, we use non-IFRSs adjusted net profit attributable to owners of the parent as an additional financial measure. We define non-IFRSs adjusted net profit attributable to owners of the parent as net profit before certain expenses/(gains): 1) share-based compensation expenses; 2) foreign exchange gains and losses and the income statement impact of the gains or losses of the corresponding foreign exchange hedging instruments; 3) realized and unrealized related gains or losses from equity investments; 4) Other incidental, non-cash or non-operating items.

The Company believes that the consideration of the non-IFRSs adjusted net profit attributable to owners of the parent by eliminating the impact of certain incidental, non-cash or non-operating items is useful for better understanding and assessing underlying business performance and operating trends for the Company's management, shareholders and potential investors.

The non-IFRSs adjusted net profit attributable to owners of the parent is not an alternative to: (i) profit before tax or net profit (as determined in accordance with IFRSs) as a measure of our operating performance, (ii) cash flows from operating, investing and financing activities as a measure of our ability to satisfy our cash needs, or (iii) any other measures of performance or liquidity. In addition, the presentation of the non-IFRSs adjusted net profit attributable to owners of the parent is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRSs. Shareholders and potential investors should not view the non-IFRSs adjusted net profit attributable to owners of the parent on a stand-alone basis or as a substitute for results under the IFRSs, or as being comparable to results reported or forecasted by other companies.

## II. COMMUNICATION STATUS WITH THE ACCOUNTING FIRM

The Company has communicated in advance with the auditors on matters related to the results estimate, and there is no major disagreement between the Company and the auditors on the financial data related to the results estimate.

The results estimate has not been audited or pre-audited by the certified public accountants.

## III. REASONS FOR CHANGES IN RESULTS

### 1. Impact of principal business

The Company remained steadfast in implementing its core strategy of developing an end-to-end, fully integrated and multiple modalities-capable services platform with global footprints. Guided by customer demand, the Company further strengthened its global operations and technological capabilities. In the first half of 2026, the Company’s revenue is estimated to increase by 16% to 19% year-on-year; and the non-IFRSs adjusted net profit attributable to owners of the parent increased by 17% to 22% year-on-year.

At the midpoint of the estimated results, in the second quarter of 2026, the Company’s revenue increased by 19.38% year-on-year; and the non-IFRSs adjusted net profit attributable to owners of the parent increased by 22.30% year-on-year.

In the first half of 2026, driven by the continued expansion of strategic customer collaborations and the progression of its small molecule CDMO service project pipelines toward later stages, the Company's newly signed purchase orders increased by more than 30% year-on-year. Within this total, its laboratory services orders grew by more than 20% year-on-year, while small molecule CDMO services orders grew by more than 50% year-on-year. The Company continued to expand its R&D and production service teams to meet the rapidly growing business demand.

### 2. Impact of non-recurring gains or losses

As mentioned above, the non-recurring gains or losses attributable to owners of the parent during the reporting period amounted to RMB53 million to RMB63 million. In the same period of last year, the non-recurring gains or losses attributable to owners of the parent were RMB64.7387 million. The non-recurring gains or losses decreased by approximately RMB1.7387 million to RMB11.7387 million.

Under the combined impact of continued growth of its core business, the one-off reorganization-related expenses of its overseas operations, and non-recurring gains or losses, the net profit attributable to owners of the parent increased by 4% to 10% year-on-year.

## IV. ADDITIONAL INFORMATION

1. The estimated data of the results disclosed in this announcement is only a preliminary estimate made by the finance department of the Company and has not been audited or pre-audited by the certified public accountants.

2. Details of the Company's interim results of 2026 prepared under the PRC Accounting Standards for Business Enterprises or IFRSs will be disclosed in the interim reports 2026 to be published by the Company on the Shenzhen Stock Exchange or The Stock Exchange of Hong Kong Limited, respectively. Investors are advised to exercise caution and pay attention to investment risks involved.

By order of the Board
**Pharmaron Beijing Co., Ltd.**
**Dr. Lou Boliang**
*Chairman*

Beijing, the PRC
July 13, 2026

*As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Li Shing Chung Gilbert as employee representative Director; Ms. Wan Xuan as non-executive Director; Ms. Li Lihua, Prof. Tsang King Fung and Ms. Shen Rong as independent non-executive Directors.*